Pelthos Therapeutics (PTHS) Price & Analysis

Compare

67 Followers

PTHS Stock Chart & Stats

$22.08

Market closed

$22.08

Day’s Range― - ―

52-Week Range$9.00 - $54.29

Previous CloseN/A

VolumeN/A

Average Volume (3M)30.94K

Market Cap

$71.38M

Enterprise Value$3.27M

Total Cash (Recent Filing)$14.25M

Total Debt (Recent Filing)$3.48M

Price to Earnings (P/E)―

Beta1.83

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding3,235,543

10 Day Avg. Volume22,109

30 Day Avg. Volume30,941

Financial Highlights & Ratios

PEG Ratio-0.15

Price to Book (P/B)-2.55

Price to Sales (P/S)0.00

P/FCF Ratio-1.20

Enterprise Value/Market Cap0.05

Enterprise Value/Revenue0.44

Enterprise Value/Gross Profit0.81

Enterprise Value/Ebitda-0.15

Forecast

1Y Price Target

$60.40

Price Target Upside173.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Commercial TractionStrong early adoption of Zelsuvmi has driven meaningful prescription increases and stable channel inventory, supporting expectations for continued sales growth.

Market Access And Salesforce ExpansionInclusion of Zelsuvmi on Medicaid formularies in several large states without prior authorization, coupled with an expanding sales force to reach more prescribers, improves patient access and potential prescription volume.

Product AcquisitionAcquisition of worldwide rights to an FDA‑approved single‑application lice therapy expands Pelthos's product lineup with a differentiated treatment that can be commercialized through existing sales infrastructure and requires no ongoing payments to the seller.

Bears Say

CompetitionA competing FDA‑approved molluscum contagiosum product with a different application method and cost profile could capture prescribers and limit Pelthos's market share in key segments.

Financing And Regulatory RiskDevelopment or regulatory setbacks and the potential need for additional capital could force dilutive financing or delay new product launches, putting pressure on the stock.

Intellectual Property RiskUnresolved intellectual property exposure could lead to litigation or limit exclusivity, risking erosion of pricing power and market position.

Pelthos Therapeutics News

Pelthos Therapeutics files $200M mixed securities shelf

16:47 EST Pelthos Therapeutics (PTHS) files $200M mixed securities shelf Published first on TheFly – the ultimate source...

11d ago

PTHS

Pelthos Therapeutics price target raised to $60 from $57 at Oppenheimer

Oppenheimer raised the firm’s price target on Pelthos Therapeutics (PTHS) to $60 from $57 and keeps an Outperform...

18d ago

PTHS

Horizon Technology provides $50M loan facility to Pelthos Therapeutics

Horizon Technology (HRZN) “announced it has provided a $50 million venture loan facility to Pelthos Therapeutics (PTHS), with...

29d ago

HRZN

PTHS

Pelthos Therapeutics Secures $50 Million Venture Loan Financing

Pelthos Therapeutics ( ($PTHS) ) has issued an announcement. On January 12, 2026, Pelthos Therapeutics and its subsidiaries...

1M ago

PTHS

Pelthos Therapeutics secures up to $50M senior secured term loan

Pelthos Therapeutics (PTHS) has secured financing from Horizon Technology Finance Corporation (HRZN), an affiliate of Monroe Capital, with...

1M ago

HRZN

PTHS

Pelthos Therapeutics Details Q1 2026 Growth Strategy

Pelthos Therapeutics ( ($PTHS) ) has issued an update. On January 6, 2026, Pelthos Therapeutics’ board, acting on...

1M ago

PTHS

Pelthos Therapeutics: Xeglyze Acquisition and Dermatology Portfolio Drive Multi‑Year Upside and Support Buy Rating

H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Pelthos Therapeutics today and set a price target...

1M ago

PTHS

Pelthos Therapeutics acquires Xeglyze topical treatment for $1.8M

Pelthos Therapeutics (PTHS) has acquired Xeglyze from Hatchtech for $1.8M. Xeglyze is a pediculicide indicated for the topical...

1M ago

PTHS

Pelthos Therapeutics Acquires Global Rights to Xeglyze

Pelthos Therapeutics ( ($PTHS) ) just unveiled an announcement. On December 23, 2025, Pelthos Therapeutics acquired from Australian...

1M ago

PTHS

Pelthos Therapeutics Adds Veteran Finance Executive to Board

An update from Pelthos Therapeutics ( ($PTHS) ) is now available. On December 23, 2025, Pelthos Therapeutics expanded...

2M ago

PTHS

Pelthos Therapeutics Concludes 2025 Annual Stockholder Meeting

The latest update is out from Pelthos Therapeutics ( ($PTHS) ). On December 17, 2025, Pelthos Therapeutics Inc....

2M ago

PTHS

Pelthos signs benefit manager agreement expanding patient access to ZELSUVMI

Pelthos Therapeutics (PTHS) announced it has signed its first commercial agreement to expand patient access for ZELSUVMI topical...

2M ago

PTHS

Lake Street starts Pelthos with a Buy on ‘category-leader potential’

As previously reported, Lake Street initiated coverage of Pelthos Therapeutics (PTHS) with a Buy rating and $50 price...

2M ago

PTHS

Pelthos Therapeutics initiated with a Buy at Lake Street

Lake Street initiated coverage of Pelthos Therapeutics (PTHS) with a Buy rating and $50 price target Published first...

2M ago

PTHS

PTHS FAQ

What was Pelthos Therapeutics’s price range in the past 12 months?

Pelthos Therapeutics lowest stock price was $9.00 and its highest was $54.29 in the past 12 months.

What is Pelthos Therapeutics’s market cap?

Pelthos Therapeutics’s market cap is $71.38M.

When is Pelthos Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Pelthos Therapeutics’s earnings last quarter?

Currently, no data Available

Is Pelthos Therapeutics overvalued?

According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pelthos Therapeutics pay dividends?

Pelthos Therapeutics does not currently pay dividends.

What is Pelthos Therapeutics’s EPS estimate?

Pelthos Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pelthos Therapeutics have?

Pelthos Therapeutics has 3,235,543 shares outstanding.

What happened to Pelthos Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pelthos Therapeutics?

Currently, no hedge funds are holding shares in PTHS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pelthos Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

5808.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pelthos Therapeutics

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Pelthos Therapeutics (PTHS) Earnings & Revenues

Historic Earnings Reports

PTHS Earnings Call

Q3 2025

0:00 / 0:00

PTHS Stock 12 Month Forecast

Average Price Target

$60.40

▲(173.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","28":"$28","44":"$44","60":"$60","76":"$76"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,28,44,60,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.3,29.123076923076923,32.94615384615385,36.769230769230774,40.59230769230769,44.41538461538462,48.238461538461536,52.06153846153846,55.88461538461539,59.70769230769231,63.53076923076924,67.35384615384616,71.17692307692307,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.3,28,30.7,33.4,36.1,38.8,41.5,44.2,46.9,49.599999999999994,52.3,55,57.7,{"y":60.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.3,27.2,29.1,31,32.9,34.8,36.7,38.6,40.5,42.4,44.3,46.2,48.099999999999994,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":36.5,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.9,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.7,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.4,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.4,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >